Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid.

[1]  K. Blennow,et al.  Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study , 2015, Neurobiology of Aging.

[2]  Tormod Fladby,et al.  A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..

[3]  R. Kaji,et al.  Reduced alpha‐synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[4]  N. Heegaard,et al.  Cerebrospinal fluid α-synuclein in the differential diagnosis of parkinsonian syndromes , 2014 .

[5]  Philip Scheltens,et al.  Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice , 2014, PloS one.

[6]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[7]  M. Carrillo,et al.  CSF biomarker variability in the Alzheimer's Association quality control program , 2013, Alzheimer's & Dementia.

[8]  B. Mollenhauer,et al.  Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects , 2013, Neuroscience Letters.

[9]  J. Molinuevo,et al.  Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.

[10]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[11]  B. Mollenhauer,et al.  Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. , 2010, Biomarkers in medicine.

[12]  M. Blankenstein,et al.  Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop , 2010, International journal of Alzheimer's disease.

[13]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[14]  R. Barbour,et al.  Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.

[15]  Juan Manuel Maler,et al.  Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. , 2006, Clinical chemistry.

[16]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[17]  K. Yeo,et al.  Lot-to-lot inconsistency of anticardiolipin reagents. , 2002, Clinical chemistry.